
SAN FRANCISCO-In a phase II trial, recombinant human keratinocyte growth factor (rHuKGF, or KGF) significantly reduced severe mucositis and improved quality of life for patients with hematologic malignancies who underwent autologous peripheral blood progenitor cell transplantation.
